KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Other Non Operating Income (2018 - 2020)

Historic Other Non Operating Income for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Q3 2020 value amounting to -$2.6 million.

  • Aurinia Pharmaceuticals' Other Non Operating Income fell 15760.2% to -$2.6 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$57.5 million, marking a year-over-year decrease of 18419.28%. This contributed to the annual value of -$41.1 million for FY2019, which is 31314.04% down from last year.
  • Aurinia Pharmaceuticals' Other Non Operating Income amounted to -$2.6 million in Q3 2020, which was down 15760.2% from $3.0 million recorded in Q2 2020.
  • Aurinia Pharmaceuticals' Other Non Operating Income's 5-year high stood at $4.5 million during Q3 2019, with a 5-year trough of -$48.0 million in Q4 2019.
  • Moreover, its 3-year median value for Other Non Operating Income was -$3.7 million (2018), whereas its average is -$9.7 million.
  • Within the past 5 years, the most significant YoY rise in Aurinia Pharmaceuticals' Other Non Operating Income was 57232.0% (2020), while the steepest drop was 15760.2% (2020).
  • Quarter analysis of 3 years shows Aurinia Pharmaceuticals' Other Non Operating Income stood at -$19.3 million in 2018, then plummeted by 148.44% to -$48.0 million in 2019, then skyrocketed by 94.58% to -$2.6 million in 2020.
  • Its Other Non Operating Income was -$2.6 million in Q3 2020, compared to $3.0 million in Q2 2020 and -$9.8 million in Q1 2020.